Cellebrite DI Ltd. has recently filed a Form 144, revealing that Holly Windham, the company's General Counsel and Chief Compliance Officer, intends to sell 11,986 shares of common stock. This sale is scheduled for November 17, 2026, and is part of a mandatory, non-discretionary arrangement to cover income tax liabilities incurred from the vesting of restricted share units.
This development is significant as it highlights the company's approach to employee compensation and tax obligations. The sale of shares by a high-ranking executive can also impact investor sentiment and market perception, particularly within the prepackaged software industry.
Background
Cellebrite DI Ltd. operates in the prepackaged software sector, classified under SIC code 7372. The company trades on the Nasdaq under the ticker symbol CLBT. It is categorized as a large accelerated filer, indicating a robust market presence and compliance with SEC regulations. Recent filings include various forms, with the latest being a Form 4 filed on November 10, 2026, just prior to the Form 144 submission.
What the Filing Says
The filing states that Windham acquired the shares on November 5, 2026, as part of her compensation package. The filing notes, "The reporting person intends to sell securities reported herein on 11/17/2026 pursuant to a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only." This indicates a structured approach to managing tax implications associated with executive compensation.
Impact
This transaction may affect various stakeholders, including investors, employees, and market analysts. Investors may scrutinize the sale for insights into the company's financial health and executive compensation practices. Employees may also view this as a reflection of the company's commitment to managing tax liabilities associated with equity compensation.
What's Next
The filing does not say what happens next regarding additional share sales or further disclosures. However, the scheduled sale date of November 17, 2026, will be a point of interest for market watchers.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










